A phase 3 randomized, double-blind, placebo-controlled trial of ganitumab or placebo in combination with gemcitabine as first-line therapy for metastatic adenocarcinoma of the pancreas: The GAMMA trial

Annals of Oncology

Volumn 26, Issue 5, 2015, Pages 921-927

  Fuchs, Charles S ^a   Azevedo, S ^b   Okusaka, T ^c   Van Laethem, J L ^d   Lipton, L R ^e   Riess, H ^f   Szczylik, C ^g   Moore, M J ^h   Peeters, M ⁱ   Bodoky, G ^j   Ikeda, M ^k   Melichar, B ^l   Nemecek, R ^m   Ohkawa, S ⁿ   Swieboda Sadlej, A ^o   Tjulandin, S A ^p   Van Cutsem, E ^q   Loberg, R ^r   Haddad, V ^s   Gansert, J L ^t   Bach, B A ^r   Carrato, A ^u   more..

^a DANA FARBER CANCER INSTITUTE   (United States)

^b HOSPITAL DE CLÍNICAS DE PORTO ALEGRE   (Brazil)

^c NATIONAL CANCER CENTER HOSPITAL   (Japan)

^d ERASME HOSPITAL   (Belgium)

^e ROYAL MELBOURNE HOSPITAL   (Australia)

^f CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^g MILITARY INSTITUTE OF MEDICINE   (Poland)

^h UNIVERSITY OF TORONTO   (Canada)

ⁱ ANTWERP UNIVERSITY HOSPITAL   (Belgium)

^j Szent Laszlo Hospital   (Hungary)

^k NATIONAL CANCER CENTER HOSPITAL EAST   (Japan)

^l PALACKÝ UNIVERSITY   (Czech Republic)

^m MASARYK MEMORIAL CANCER INSTITUTE   (Czech Republic)

ⁿ KANAGAWA CANCER CENTER   (Japan)

^o MEDICAL UNIVERSITY OF WARSAW   (Poland)

^p N N BLOKHIN RUSSIAN CANCER RESEARCH CENTER   (Russian Federation)

^q UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^r AMGEN INC   (United States)

^s AMGEN LTD   (United Kingdom)

^t Global Development   (United States)

^u HOSPITAL RAMÓN Y CAJAL   (Spain)

more..

Author keywords

Biomarker; Ganitumab; Gemcitabine; IGF 1 receptor; Pancreatic cancer

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; GANITUMAB; GEMCITABINE; PLACEBO; SOMATOMEDIN BINDING PROTEIN 2; SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN C; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC ANTIMETABOLITE; DEOXYCYTIDINE; MONOCLONAL ANTIBODY; TUMOR MARKER;

ABDOMINAL PAIN; ADULT; AGED; ANEMIA; ARTICLE; ASTHENIA; CANCER COMBINATION CHEMOTHERAPY; CONSTIPATION; CONTROLLED STUDY; DECREASED APPETITE; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; FATIGUE; FEMALE; FEVER; HUMAN; HYPERGLYCEMIA; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PANCREAS ADENOCARCINOMA; PANCREAS METASTASIS; PERIPHERAL EDEMA; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; RASH; THROMBOCYTOPENIA; VOMITING; WEIGHT REDUCTION; ADENOCARCINOMA; ANALOGS AND DERIVATIVES; BLOOD; CLINICAL TRIAL; DISEASE COURSE; DISEASE FREE SURVIVAL; DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; KAPLAN MEIER METHOD; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; PANCREATIC NEOPLASMS; PATHOLOGY; PROPORTIONAL HAZARDS MODEL; SECONDARY; TIME FACTOR; TREATMENT OUTCOME; VERY ELDERLY;

ADENOCARCINOMA; ADMINISTRATION, INTRAVENOUS; ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOMARKERS, TUMOR; DEOXYCYTIDINE; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; PANCREATIC NEOPLASMS; PROPORTIONAL HAZARDS MODELS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84929083437     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdv027     Document Type: Article

References (28)

1. SEER Stat Fact Sheets: Pancreas Cancer. National Cancer Institute. http://seer.cancer.gov/statfacts/html/pancreas.html (3 March 2014, date last accessed).
2. Baxter NN, Whitson BA, Tuttle TM. Trends in the treatment and outcome of pancreatic cancer in the United States. Ann Surg Oncol 2007; 14: 1320-1326.
3. Tempero M, Plunkett W, Ruiz Van Haperen V et al. Randomized phase II comparison of dose-intense gemcitabine: thirty-minute infusion and fixed dose rate infusion in patients with pancreatic adenocarcinoma. J Clin Oncol 2003; 21: 3402-3408.
4. NCCN Clinical Practice Guidelines in Oncology: Pancreatic Adenocarcinoma v.1.2014. Fort Washington, PA: National Comprehensive Cancer Network, 2014.
5. Seufferlein T, Bachet JB, Van Cutsem E, Rouqier P, ESMO Guidelines Working Group. Pancreatic adenocarcinoma: ESMO-ESDO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2012; 23(Suppl 7): vii33-vii40.
6. Von Hoff DD, Ervin T, Arena FP et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med 2013; 369: 1691-1703.
7. Abraxane® (nab-paclitaxel). Full Prescribing Information. Summit, NJ: Celgene Corporation, 2013.
8. Arnaldez FI, Helman LJ. Targeting the insulin growth factor receptor 1. Hematol Oncol Clin North Am 2012; 26: 527-542, vii-viii.
9. Bergmann U, Funatomi H, Yokoyama M, Beger HG, Korc M. Insulin-like growth factor I overexpression in human pancreatic cancer: evidence for autocrine and paracrine roles. Cancer Res 1995; 55: 2007-2011.
10. Hakam A, Fang Q, Karl R, Coppola D. Coexpression of IGF-1R and c-Src proteins in human pancreatic ductal adenocarcinoma. Dig Dis Sci 2003; 48: 1972-1978.
11. Beltran PJ, Mitchell P, Chung YA et al. AMG 479, a fully human anti-insulin-like growth factor receptor type I monoclonal antibody, inhibits the growth and survival of pancreatic carcinoma cells. Mol Cancer Ther 2009; 8: 1095-1105.
12. Kindler HL, Richards DA, Garbo LE et al. A randomized, placebo-controlled phase 2 study of ganitumab (AMG 479) or conatumumab (AMG 655) in combination with gemcitabine in patients with metastatic pancreatic cancer. Ann Oncol 2012; 23: 2834-2842.
13. Lu J, Deng H, Tang R et al. Exposure-response (E-R) analysis to facilitate phase III (P3) dose selection for ganitumab (GAN, AMG 479) in combination with gemcitabine (G) to treat metastatic pancreatic cancer (mPC). J Clin Oncol 2011; 29: abstr 4049.
14. Therasse P, Arbuck SG, Eisenhauer EA et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92: 205-216.
15. Tolcher AW, Sarantopoulos J, Patnaik A et al. Phase I, pharmacokinetic, and pharmacodynamic study of AMG 479, a fully human monoclonal antibody to insulin-like growth factor receptor 1. J Clin Oncol 2009; 27: 5800-5807.
16. McCaffery I, Tudor Y, Deng H et al. Putative predictive biomarkers of survival in patients with metastatic pancreatic adenocarcinoma treated with gemcitabine and ganitumab, an IGF1R inhibitor. Clin Cancer Res 2013; 19: 4282-4289.
17. Furuse J. Pancreatic cancer: is combination treatment better? Clin Pract 2013; 10: 695-700.
18. Conroy T, Desseigne F, Ychou M et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 2011; 364: 1817-1825.
19. Hixon ML, Gualberto A, Demers L et al. Correlation of plasma levels of free insulinlike growth factor 1 and clinical benefit of the IGF-IR inhibitor figitumumab (CP-751, 871). J Clin Oncol 2009; 27: abstr 3539.
20. Van Cutsem E, Vervenne WL, Bennouna J et al. Phase III trial of bevacizumab in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer. J Clin Oncol 2009; 27: 2231-2237.
21. Lambrechts D, Claes B, Delmar P et al. VEGF pathway genetic variants as biomarkers of treatment outcome with bevacizumab: an analysis of data from the AViTA and AVOREN randomised trials. Lancet Oncol 2012; 13: 724-733.
22. Pollak M. The insulin receptor/insulin-like growth factor receptor family as a therapeutic target in oncology. Clin Cancer Res 2012; 18: 40-50.
23. Hezel AF, Kimmelman AC, Stanger BZ, Bardeesy N, Depinho RA. Genetics and biology of pancreatic ductal adenocarcinoma. Genes Dev 2006; 20: 1218-1249.
24. Almoguera C, Shibata D, Forrester K et al. Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes. Cell 1988; 53: 549-554.
25. Appleman VA, Ahronian LG, Cai J, Klimstra DS, Lewis BC. KRAS(G12D)-and BRAF (V600E)-induced transformation of murine pancreatic epithelial cells requires MEK/ERK-stimulated IGF1R signaling. Mol Cancer Res 2012; 10: 1228-1239.
26. Yee D. Insulin-like growth factor receptor inhibitors: baby or the bathwater? J Natl Cancer Inst 2012; 104: 975-981.
27. Atzori F, Tabernero J, Cervantes A et al. A phase I pharmacokinetic and pharmacodynamic study of dalotuzumab (MK-0646), an anti-insulin-like growth factor-1 receptor monoclonal antibody, in patients with advanced solid tumors. Clin Cancer Res 2011; 17: 6304-6312.
28. Cohn AL, Tabernero J, Maurel J et al. A randomized, placebo-controlled phase 2 study of ganitumab or conatumumab in combination with FOLFIRI for second-line treatment of mutant KRAS metastatic colorectal cancer. Ann Oncol 2013; 24: 1777-1785.